ArticleJournal of translational medicine2026
Molecular characterisation of telitacicept response phenotypes in systemic lupus erythematosus: an exploratory integrated transcriptome and B-cell receptor repertoire profiling study.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundTelitacicept, a dual BAFF/APRIL inhibitor, has shown clinical efficacy in systemic lupus erythematosus (SLE), but the underlying molecular mechanisms remain incompletely understood.
methodsWe performed an integrative longitudinal study in ten patients with SLE before and after telitacicept treatment, alongside ten healthy controls. Paired transcriptome RNA sequencing and dedicated B-cell receptor (BCR) sequencing and repertoire analysis were integrated with serial clinical phenotyping including SLEDAI-2 K, anti-dsDNA antibodies, and complement C3/C4 levels over 12 months of follow-up. Differential expression analysis, pathway enrichment, cell deconvolution, and BCR clonal tracking were conducted.
resultsTelitacicept treatment was associated with reduced B-cell clonal diversity and decreased estimated plasma cell abundance, alongside partial reconstitution of naive B cells. Downregulation of PI3K-Akt and NF-κB pathway genes was observed. BCR repertoire analysis suggested loss of 58.7% of clones expressing IGHV4-34, IGHV3-30, and IGHV1-46, which correlated positively with baseline disease activity scores. An unexpected upregulation of interferon-stimulated genes (ISGs) was noted post-treatment, a signature not observed in independent cohorts receiving standard-of-care therapies. Exploratory subgrouping based on ISG dynamics suggested potential differences in clinical trajectory: the ISG-upregulated subgroup showed a more pronounced initial reduction in SLEDAI-2 K scores at three months, followed by a subsequent increase in disease activity scores during extended follow-up, whereas the non-upregulated subgroup maintained relatively stable scores.
conclusionsThese preliminary findings suggest that telitacicept may remodel the B-cell repertoire while concurrently modulating interferon pathways in SLE. The observed ISG upregulation generates hypotheses regarding post-treatment immune dynamics that warrant validation in larger, independent cohorts.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.